I am a
Home I AM A Search Login

Papers of the Week


2019 Jul


United European Gastroenterol J


7


6

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease.

Authors

Hanžel J, Sever N, Ferkolj I, Štabuc B, Smrekar N, Kurent T, Koželj M, Novak G, Compernolle G, Tops S, Gils A, Drobne D
United European Gastroenterol J. 2019 Jul; 7(6):741-749.
PMID: 31316778.

Abstract

The relationship between vedolizumab trough levels and combined endoscopic and clinical remission is unknown.